High level of discordant IGRA results in HIV-infected adults and children.

Department of Pediatrics, School of Medicine, Case Western Reserve University, Cleveland, Ohio 44106, USA.
The International Journal of Tuberculosis and Lung Disease (Impact Factor: 2.76). 04/2008; 12(4):417-23.
Source: PubMed

ABSTRACT Tygerberg district, Western Cape Province, South Africa.
To measure the agreement of two interferon-gamma release assays (IGRAs) and the tuberculin skin test (TST) for the detection of Mycobacterium tuberculosis infection in human immunodeficiency virus (HIV) infected adults and children in a setting highly endemic for tuberculosis (TB).
Cross-sectional study.
In HIV-infected adults (n=20) and children (n=23), tests yielded discordant results, with 61% of individuals testing positive with T-SPOT.TB, 41% with TST and 28% with QuantiFERON TB Gold (QTF). In children, there was poor agreement between the TST and T-SPOT.TB (kappa [kappa]=-0.02), but moderate agreement between the TST and QTF (kappa=0.44). In adults, there was moderate agreement between the TST and T-SPOT.TB (kappa=0.43), and the TST and QTF (kappa = 0.46). In children and adults, there was fair agreement between the T-SPOT.TB and QTF (kappa=0.33). Twenty per cent of adults had >or=1 indeterminate IGRA results.
There is poor to moderate agreement between the TST and IGRAs in HIV-infected adults and children. T-SPOT.TB may have improved sensitivity for detection of M. tuberculosis infection in HIV-infected individuals compared to the QTF and the TST. In HIV-infected individuals, IGRA test properties are affected by test cut-off point and nil control responses.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: HIV infected children are at increased risk of TB disease and require annual TB screening. Data on use of IGRA for TB screening in them are limited. We retrospectively evaluated the usefulness of Quantiferon Gold-in-tube test (QFT), an IGRA in screening for LTBI in relatively healthy, immunologically stable HIV infected children.
    BMC Infectious Diseases 09/2014; 14(1):516. DOI:10.1186/1471-2334-14-516 · 2.56 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: Data on the performance of interferon-gamma release assays (IGRAs), QuantiFERON TB Gold In-tube (QFNGIT) and T-Spot. TB, in diagnosing tuberculosis (TB) are limited in Southeast Asia. This study aims to compare the performances of the two IGRAs and TST in Thai children with recent TB exposure. Methods: This multicenter, prospective study enrolled children with recent exposure to active TB adults. Children were investigated for active TB. TST was performed and blood collected for T-Spot. TB and QFNGIT. Results: 158 children were enrolled (87% TB-exposed and 13% active TB, mean age 7.2 years). Only 3 children had HIV infection. 66.7% had TST >= 10 mm, while 38.6% had TST >= 15 mm. 32.5% had positive QFNGIT; 29.9% had positive T-Spot. TB. QFNGIT and T-Spot. TB positivity was higher among children with active TB compared with TB-exposed children. No indeterminate IGRA results were detected. No statistically significant differences between the performances of the IGRAs and TST at the two cut-offs with increasing TB exposure were detected. Concordance for positive IGRAs and TST ranged from 42-46% for TST >= 10 mm and 62-67% for TST >= 15 mm. On multivariable analyses, exposure to household primary/secondary caregiver with TB was associated with positive QFNGIT. Higher TB contact score and active TB were associated with positive T-Spot. TB. Conclusions: Both QFNGIT and T-Spot. TB performed well in our Thai pediatric study population. No differences in the performances between tests with increasing TB exposure were found. Due to accessibility and low cost, using TST may more ideal than IGRAs in diagnosing latent and active TB in healthy children in Thailand and other similar settings.
    PLoS ONE 08/2014; 9(8):e105003. DOI:10.1371/journal.pone.0105003 · 3.53 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: La tuberculosis (TBC) es una de las principales causas de muerte en el mundo en individuos con infección por VIH. En Chile, su incidencia en la población general se ha reducido significativamente y esta enfermedad se ha ido centrando en grupos de alto riesgo, en particular los inmuno suprimidos. En estos pacientes las pruebas diagnósticas tienen sensibilidad inferior y la enfermedad evoluciona con mayor frecuencia hacia formas diseminadas y rápidamente progresivas. El tratamiento simultáneo de la infección por VIH y la enfermedad tuberculosa aumenta la complejidad al sumar toxicidades e interacciones. En este artículo revisamos las particularidades y los avances que han surgido, tanto en el diagnóstico como el tratamiento de la TBC, en el paciente co-infectado con VIH.
    Revista chilena de infectologia: organo oficial de la Sociedad Chilena de Infectologia 04/2009; 26(2):126-134. DOI:10.4067/S0716-10182009000200003 · 0.50 Impact Factor


Available from
Jan 28, 2015